Moderna nabs funding to make vaccine against China coronavirus 
 The Coalition for Epidemic Preparedness Innovations (CEPI), a public-private coalition aimed at accelerating the development of vaccines, has agreed to fundÂ the manufacture of Moderna's (MRNA ) mRNA vaccine against the coronavirus causing the outbreak in China, named 2019-nCoV.

NIH's National Institute of Allergy and Infectious Diseases (NIAID), Moderna's collaborator on the design of the vaccine, will conduct IND-enabling studies as well as a Phase 1 clinical trial.